Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal Donor Natural Killer Cells are an immunotherapy treatment derived from healthy donors who have undergone FDA-mandated screening. These cells are part of the innate immune system and can destroy infected and diseased cells, particularly cancer cells, without prior exposure to pathogens. They function as the first line of defense against infection and disease, recognizing and killing abnormal cells through various receptors. The therapy involves infusing these pre-prepared NK cells into patients, particularly those with cancer such as acute myeloid leukemia (AML). The cells are immediately available 'off-the-shelf,' eliminating manufacturing delays associated with patient-specific therapies like CAR-T cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Universal Donor Natural Killer Cells.